[go: up one dir, main page]

AR121597A1 - Formulaciones de un agonista del receptor farnesoide x - Google Patents

Formulaciones de un agonista del receptor farnesoide x

Info

Publication number
AR121597A1
AR121597A1 ARP210100668A ARP210100668A AR121597A1 AR 121597 A1 AR121597 A1 AR 121597A1 AR P210100668 A ARP210100668 A AR P210100668A AR P210100668 A ARP210100668 A AR P210100668A AR 121597 A1 AR121597 A1 AR 121597A1
Authority
AR
Argentina
Prior art keywords
farnesoid
hpmcas
hpmc
eudragit
receptor agonist
Prior art date
Application number
ARP210100668A
Other languages
English (en)
Inventor
Nicholas D Smith
Robert Mansfield
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of AR121597A1 publication Critical patent/AR121597A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se describen las formulaciones farmacéuticas de un agonista del receptor farnesoide X, 3-hidroxiazetidina-trans-1-carboxilato de 4-((4-(1-(tert-butil)-1H-pirazol-4-il)piridin-2-il)((4-(4-metoxi-3-metilfenil)biciclo[2.2.2]octan-1-il)metil)carbamoil)ciclohexilo, y métodos para utilizar tales formulaciones farmacéuticas en el tratamiento de afecciones, enfermedades o trastornos asociados a la actividad del receptor farnesoide X. Reivindicación 2: La dispersión sólida secada por aspersión de la reivindicación 1, caracterizada por que el polímero farmacéuticamente aceptable se selecciona de PVP / VA 64, PVP 30, HPMCAS-L, HPMCAS-M, HPMCAS-H, Eudragit L100-55, Eudragit L100, Eudragit EPO, HPMC E15, HPMC E3, HPMC E5, HPMCP-HP55 y Soluplus.
ARP210100668A 2020-03-18 2021-03-17 Formulaciones de un agonista del receptor farnesoide x AR121597A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062991216P 2020-03-18 2020-03-18

Publications (1)

Publication Number Publication Date
AR121597A1 true AR121597A1 (es) 2022-06-22

Family

ID=75478197

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100668A AR121597A1 (es) 2020-03-18 2021-03-17 Formulaciones de un agonista del receptor farnesoide x

Country Status (9)

Country Link
US (1) US20230120914A1 (es)
EP (1) EP4121012A1 (es)
JP (1) JP2023518398A (es)
KR (1) KR20220155596A (es)
CN (1) CN115666528A (es)
AR (1) AR121597A1 (es)
AU (1) AU2021239956A1 (es)
BR (1) BR112022018553A2 (es)
WO (1) WO2021188695A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI833805B (zh) 2018-09-18 2024-03-01 美商奧加諾沃公司 類法尼醇x(farnesoid x)受體促效劑及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037482A1 (en) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
PL3043865T3 (pl) * 2013-09-11 2021-07-05 Institut National De La Santé Et De La Recherche Médicale (Inserm) SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B
EP3350164A4 (en) * 2015-09-16 2019-03-27 Metacrine, Inc. X FARNESOID RECEPTOR AGONISTS AND USES THEREOF
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
EP3596053B1 (en) * 2017-03-15 2023-08-16 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
AU2018236275B2 (en) * 2017-03-15 2022-05-12 Organovo, Inc. Farnesoid X receptor agonists and uses thereof
US20200131129A1 (en) * 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CZ2017298A3 (cs) * 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
BR112021004931A2 (pt) * 2018-09-18 2021-06-01 Metacrine, Inc. formas cristalinas de um agonista de receptor farnesoide x
TWI833805B (zh) * 2018-09-18 2024-03-01 美商奧加諾沃公司 類法尼醇x(farnesoid x)受體促效劑及其用途

Also Published As

Publication number Publication date
CN115666528A (zh) 2023-01-31
US20230120914A1 (en) 2023-04-20
BR112022018553A2 (pt) 2022-11-29
JP2023518398A (ja) 2023-05-01
KR20220155596A (ko) 2022-11-23
WO2021188695A1 (en) 2021-09-23
EP4121012A1 (en) 2023-01-25
TW202143962A (zh) 2021-12-01
AU2021239956A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
Gonzalez-Rothi et al. Intermittent hypoxia and neurorehabilitation
US10980741B2 (en) Compositions and methods for treating pterygium recurrence
Baptiste et al. Update on the treatment of spinal cord injury
Schopf et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles
JP2019167350A5 (es)
AR121597A1 (es) Formulaciones de un agonista del receptor farnesoide x
JP6860502B2 (ja) １−（３−（２−（１−ベンゾチオフェン−５−イル）エトキシ）プロピル）アゼチジン−３−オールまたはその塩を含む錠剤
JP2021191771A5 (es)
CN104080443A (zh) 含酸式羧甲基纤维素的崩解性颗粒组合物的制法、及该组合物和含该组合物的口腔崩解片剂
JP2017505822A5 (es)
EP4297871A1 (en) Methods and compositions for treating agitation
UA128017C2 (uk) Композиція і спосіб лікування розладу, що послаблюється активацією мускаринових рецепторів (варіанти)
TW200407111A (en) MODAFINIL pharmaceutical compositions
Zhang et al. Delayed transplantation of human neurons following brain injury in rats: a long-term graft survival and behavior study
TW201444589A (zh) 錠劑型式
US12213995B2 (en) Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
WO2021155254A1 (en) Amorphous nilotinib microparticles and uses thereof
KR101802514B1 (ko) Ｎｍ를 포함하는 염증성 질환의 예방 또는 치료용 조성물
CN105517576A (zh) 超速崩解片剂及其制备方法
CN104822392A (zh) 抑制活化的t-细胞中il-22表达的方法
US20090186854A1 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
JP2023540665A (ja) ＲＯＲγＴ阻害剤及びそれらの局所使用
O’Donnell et al. Emerging Approaches for Regenerative Rehabilitation Following Traumatic Brain Injury: Regenerative Rehabilitation in TBI
US20230172945A1 (en) Application of compounds in controlling or killing mites
Friedlander Advances in treatment and management: immunologic and cell-based regenerative therapies